Goldman Sachs revealed it has been working with Anthropic over the last six months to build AI agents that automate accounting, compliance, and client onboardingGoldman Sachs revealed it has been working with Anthropic over the last six months to build AI agents that automate accounting, compliance, and client onboarding

Goldman Sachs And Anthropic Develop AI Agents For Accounting, Compliance, And Client Onboarding

2026/02/09 21:50
3 min read
Goldman Sachs And Anthropic Develop AI Agents For Accounting, Compliance, And Client Onboarding

Goldman Sachs, a major global financial institution, has disclosed that it has spent the past six months collaborating with AI safety and research company Anthropic to develop autonomous AI agents designed to automate tasks in accounting, compliance, and client onboarding.

According to Marco Argenti, Goldman’s chief information officer, the bank has been working closely with embedded engineers from Anthropic to co-develop these agents, focusing initially on accounting for trades and transactions as well as client vetting and onboarding. 

The initiative is still in its early stages, with the agents being built on Anthropic’s Claude model, which Argenti said is expected to significantly reduce the time required to complete these essential processes. While he indicated a launch is forthcoming, no specific timeline was provided. Marco Argenti described the technology as functioning like a “digital co-worker” for roles within the firm that are highly process-intensive and complex.

Claude demonstrated capabilities beyond coding, showing promise in areas requiring the parsing of large datasets and documents while applying rules and judgment, such as accounting and compliance. The firm has concluded that similar levels of automation could be applied across other process-heavy areas of the organization.

The implementation of these agents is expected to accelerate client onboarding and improve the efficiency of trade reconciliation and other accounting functions. The future applications could include tasks such as producing investment banking pitchbooks or internal monitoring functions, though he emphasized that it is too early to anticipate direct job reductions in the departments where AI will be deployed. However, the bank may eventually reduce reliance on third-party service providers as the technology matures.

The objective of the initiative is to enhance operational capacity, allowing processes to be completed more quickly, improving the client experience, and supporting business growth.

Goldman Sachs Launches Multiyear Generative AI Overhaul, Expands Use Of Autonomous Tools 

Goldman Sachs CEO David Solomon announced in October that the bank was beginning a multiyear transformation to reorganize around generative AI, the technology that gained widespread attention following the introduction of OpenAI’s ChatGPT in late 2022. Even as the bank continues to generate strong revenue from trading and advisory activities, Solomon noted that the overhaul would aim to limit headcount growth in certain areas.

The development comes amid a period of market turbulence for software companies and their credit providers, triggered by model updates from Anthropic, which was co-founded by a former OpenAI executive. Investors have been closely watching to determine which firms will benefit from AI adoption.

Goldman began exploring autonomous AI tools last year with the launch of Devin, an AI coding assistant that has since been made widely available to the bank’s engineering teams. 

The post Goldman Sachs And Anthropic Develop AI Agents For Accounting, Compliance, And Client Onboarding appeared first on Metaverse Post.

Market Opportunity
SIX Logo
SIX Price(SIX)
$0.00945
$0.00945$0.00945
+0.21%
USD
SIX (SIX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26